H
Helen Han
Researcher at University of Pittsburgh
Publications - 4
Citations - 228
Helen Han is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 208 citations.
Papers
More filters
Journal ArticleDOI
Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.
Helen Han,Jan F. Silverman,Tibetha S. Santucci,Robin S. Macherey,Thomas A. d’Amato,Ming Y. Tung,Robert J. Weyant,Rodney J. Landreneau +7 more
TL;DR: High VEGF expression, tumor size, and angiolymphatic invasion emerged as three independent factors predicting worsening prognosis using multivariate analysis.
Journal ArticleDOI
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Komal Jhaveri,Helen Han,Efrat Dotan,D. Oh,Cristiano Ferrario,Anthony W. Tolcher,K.‐W. Lee,Connie Liao,Y.-K. Kang,Y. Kim,E. Hamilton,Alexander I. Spira,Nikunj Patel,Christos S. Karapetis,So Young Rha,Linda D. Boyken,Joseph Woolery,P. Y. Bedard +17 more
TL;DR: ZW49 is a novel ADC comprised of a HER2-targeting bispecific antibody (directed against 2 non-overlapping HER2 epitopes) attached to a proprietary auristatin toxin with a protease-cleavable linker as mentioned in this paper .
Journal ArticleDOI
1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results
T. Jindal,Helen Han,P. S. Deshmukh,I De Kouchkovsky,Daniel Kwon,Hala T. Borno,Vadim S. Koshkin,A. Desai,Rohit Bose,Jonathan Chou,Terence W. Friedlander,Eric J. Small,Austin Nicholas Angelidakis,M. Johnson,Shi-Ting Feng,Amita Patnaik,Lawrence Fong,Joshi J. Alumkal,Rahul Aggarwal +18 more
TL;DR: ZEN is a potent and selective BET bromodomain inhibitor (BETi) with encouraging clinical activity in combination with ENZ in patients with second generation androgen receptor signaling inhibitor (ARSI)-resistant mCRPC as mentioned in this paper .
Posted ContentDOI
MD-ALL: an Integrative Platform for Molecular Diagnosis of B-cell Acute Lymphoblastic Leukemia
TL;DR: Zhang et al. as discussed by the authors introduced MD-ALL (Molecular Diagnosis of ALL), a user-friendly platform featuring sensitive and accurate B-ALL classification based on gene expression profiles (GEPs) and sentinel genetic alterations.